<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02532660</url>
  </required_header>
  <id_info>
    <org_study_id>Laboratório Catarinense SA</org_study_id>
    <nct_id>NCT02532660</nct_id>
  </id_info>
  <brief_title>Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode</brief_title>
  <acronym>LABCATTCJUSS</acronym>
  <official_title>Fase II/III Study to Evaluate the Efficacy of LABCAT TCJUSS in Patients With Depressive Episode</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Laboratório Catarinense SA</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Universidade Federal do Ceara</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Financiadora de Estudos e Projetos</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Laboratório Catarinense SA</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Evaluate the therapeutic effects of Escitalopram versus an association of Escitalopram +
      Trichilia catigua Dry Extract (LABCAT TCJUSS) in the average alteration on depression score
      measured by the Hamilton Scale (HAM-D).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Evaluate the therapeutic effects of Escitalopram versus an association of Escitalopram +
      LABCAT TCJUSS in the following aspects:

        1. Alteration on the average score of anhedonia symptoms through the Shaps-C Scale;

        2. Alteration of average scores of Global Clinical Impression carried out by the
           investigator (CGI-S e CGI-I);

        3. Average scores of the Patient Global Evaluation
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>November 2016</start_date>
  <completion_date type="Anticipated">December 2017</completion_date>
  <primary_completion_date type="Anticipated">December 2017</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>HAM-D SCORE REDUCTION</measure>
    <time_frame>WEEKS 2 (Visit 2), 4 (Visit 3), 8 (Visit 4) and 10 (Visit 5)</time_frame>
    <description>A comparison will be performed between groups in mean reduction in the HAM-D score between baseline (V1-D1) and at weeks 2 (V2), 4 (V3), 8 (V4) and 10 (V5) treatment, following the primary and secondary described outcomes.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of symptoms of anhedonia by the change in mean score of Shaps-C scale of pleasure</measure>
    <time_frame>WEEKS 2 (Visit 2), 4 (Visit 3), 8 (Visit 4) and 10 (Visit 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean scores of Clinical Global Impression performed by the investigator (CGI-I - Improvement)</measure>
    <time_frame>WEEKS 2 (Visit 2), 4 (Visit 3), 8 (Visit 4) and 10 (Visit 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean scores of Clinical Global Impression performed by the investigator (CGI-S - Severity)</measure>
    <time_frame>WEEKS 2 (Visit 2), 4 (Visit 3), 8 (Visit 4) and 10 (Visit 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean scores of Global Patient Evaluation scale</measure>
    <time_frame>WEEKS 2 (Visit 2), 4 (Visit 3), 8 (Visit 4) and 10 (Visit 5)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in mean scores of the of Arizona Sexual Experiences scale (ASEX)</measure>
    <time_frame>WEEKS 2 (Visit 2), 4 (Visit 3), 8 (Visit 4) and 10 (Visit 5)</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">282</enrollment>
  <condition>Depression</condition>
  <arm_group>
    <arm_group_label>Escitalopram + LABCAT TCJUSS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram 10mg + LABCAT TCJUSS 1000 mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram + LABCAT TCJUSS placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Escitalopram 10mg + LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Escitalopram Placebo + LABCAT TCJUSS</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Escitalopram Placebo + LABCAT TCJUSS 1000 mg daily (2 capsules in the morning + 2 capsules at night).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram 10mg</intervention_name>
    <description>Escitalopram 10mg (1 pill once a day)</description>
    <arm_group_label>Escitalopram + LABCAT TCJUSS</arm_group_label>
    <arm_group_label>Escitalopram + LABCAT TCJUSS placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABCAT TCJUSS</intervention_name>
    <description>LABCAT TCJUSS 1000mg daily (two 250mg capsules in the morning + 2 capsules of 250 mg at night)</description>
    <arm_group_label>Escitalopram + LABCAT TCJUSS</arm_group_label>
    <arm_group_label>Escitalopram Placebo + LABCAT TCJUSS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>LABCAT TCJUSS Placebo</intervention_name>
    <description>LABCAT TCJUSS placebo daily (2 capsules in the morning + 2 capsules at night);</description>
    <arm_group_label>Escitalopram + LABCAT TCJUSS placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Escitalopram Placebo</intervention_name>
    <description>Escitalopram Placebo (1 pill once a day)</description>
    <arm_group_label>Escitalopram Placebo + LABCAT TCJUSS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects from both sexes aged between 18 and 65 years;

          -  Patient diagnosed with mild depression episode confirmed by psychiatric and
             psychometric evaluation, presenting basal scores above 08 and below 24 measured by the
             Hamilton Rating Scale (HAM-D);

          -  Capable of understanding the nature and objective of the study, including risks and
             adverse effects and intended to cooperate with the researcher and act in accordance
             with the requirements of the entire protocol, which comes to be confirmed by signing
             the informed consent.

        Exclusion Criteria:

          -  Have a known hypersensitivity to Trichilia catigua or history of serious adverse
             reactions;

          -  Shows risk of suicide, assault, murder or moral exposure;

          -  Clinical history of bleeding disorders;

          -  Drug addiction, including alcohol;

          -  Known or suspected neoplasia;

          -  Knowledge positive test result for the human immunodeficiency virus;

          -  Patient not willing to adhere to the procedures of the Protocol;

          -  For women, can not be pregnant or nursing and must be in use of a contraception method
             during the participation in the study;

          -  Patients using other drugs with sedative or antidepressant action, which can not be
             suspended for 15 days (wash out);

          -  Diabetics;

          -  Hyperthyroidism;

          -  Participation in any experimental study or use of any experimental drug three months
             before the start of this study;

          -  Has any condition which the investigator deems relevant to the non-participation of
             the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Maria Elisabete Moraes</last_name>
    <role>Principal Investigator</role>
    <affiliation>Universidade Federal do Ceara (UFC)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Ana Carolina Kruger</last_name>
    <phone>+55 47 34519091</phone>
    <email>carol@catarinensepharma.com.br</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Angelita Boldieri</last_name>
    <phone>+55 47 3451 9139</phone>
    <email>angelita@catarinensepharma.com.br</email>
  </overall_contact_backup>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2015</study_first_submitted>
  <study_first_submitted_qc>August 25, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 26, 2015</study_first_posted>
  <last_update_submitted>October 13, 2016</last_update_submitted>
  <last_update_submitted_qc>October 13, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 17, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citalopram</mesh_term>
    <mesh_term>Dexetimide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

